July 30, 2024
Tilray Brands Reports Record Financial Results, Achieves 26% Net Revenue Growth
Record Fiscal 2024 Gross Profit Reduced Net Convertible Debt by ~$300 Million in Fiscal 2024 Fiscal 2024 Net Revenue Reaches…
Pharmaceuticals, Biotechnology and Life Sciences
Record Fiscal 2024 Gross Profit Reduced Net Convertible Debt by ~$300 Million in Fiscal 2024 Fiscal 2024 Net Revenue Reaches…
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on…
FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage…
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a…
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J.,…
Primary and Secondary Endpoints Achieved with Favorable Tolerability and Safety ProfileALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical,…
Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior…
TORONTO and HAIFA, Israel, July 29, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the…
LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing…
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating,…